Cargando…
Lipid flippase dysfunction as a therapeutic target for endosomal anomalies in Alzheimer’s disease
Endosomal anomalies because of vesicular traffic impairment have been indicated as an early pathology of Alzheimer’| disease (AD). However, the mechanisms and therapeutic targets remain unclear. We previously reported that βCTF, one of the pathogenic metabolites of APP, interacts with TMEM30A. TMEM3...
Autores principales: | Kaneshiro, Nanaka, Komai, Masato, Imaoka, Ryosuke, Ikeda, Atsuya, Kamikubo, Yuji, Saito, Takashi, Saido, Takaomi C., Tomita, Taisuke, Hashimoto, Tadafumi, Iwatsubo, Takeshi, Sakurai, Takashi, Uehara, Takashi, Takasugi, Nobumasa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857600/ https://www.ncbi.nlm.nih.gov/pubmed/35243232 http://dx.doi.org/10.1016/j.isci.2022.103869 |
Ejemplares similares
-
The Pursuit of the “Inside” of the Amyloid Hypothesis—Is C99 a Promising Therapeutic Target for Alzheimer’s Disease?
por: Takasugi, Nobumasa, et al.
Publicado: (2023) -
TMEM30A is a candidate interacting partner for the β-carboxyl-terminal fragment of amyloid-β precursor protein in endosomes
por: Takasugi, Nobumasa, et al.
Publicado: (2018) -
Ex vivo analysis platforms for monitoring amyloid precursor protein cleavage
por: Kamikubo, Yuji, et al.
Publicado: (2023) -
FTY720/Fingolimod, a Sphingosine Analogue, Reduces Amyloid-β Production in Neurons
por: Takasugi, Nobumasa, et al.
Publicado: (2013) -
The phospholipid flippase ATP9A is required for the recycling pathway from the endosomes to the plasma membrane
por: Tanaka, Yoshiki, et al.
Publicado: (2016)